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CD19+ cells should be excluded to prevent monocyte and B cell
contamination. Description and representative FACS plots of ﬁdel-
ity minus, isotype controls and mean ﬂuorescent intensity with
mean cell expression values should be included. We believe that
this will ensure a robust body of literature with ﬂow data that is
reasonably comparable between studies, strengthening our
understanding of this important cell type in chronic HCV infection
without increasing unnecessary conﬂicts within the literature.
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Fig. 1. CD56dimCD16neg NK cells, HCV treatment outcome, and the impact of
live/dead staining. (A) Pretreatment CD56dimCD16neg NK cells in 24 HCV patients
who have achieved SVR (triangles) and failed treatment (inverted triangles, mean
7.4 and 8.4%, respectively p = not signiﬁcant). (B) CD56dim NK cell proportion and
treatment outcome (mean 92.5 and 88.4%, respectively p = not signiﬁcant).
(C) CD56 and CD16 expression in an NK cell population from which dead cells
have not been excluded. (D) Alive/dead staining on CD56dimCD16neg NK cells
highlighted quadrant in (C) shown by black line. Solid grey population represents
the cells from the other 3 quadrants of CD56bright or CD16+ NK cells. (E) The
proportion of NK cells which are dead, stain positive in CD56dimCD16neg gate and
from the remaining CD56bright or CD16+ gates. Mean and SEM shown.
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To the Editor:
We thank Pembroke and colleagues for the comments to our
paper which, we are pleased to note, is generating interest in
the small community of liver immunologists. Contrary to our data,
they found no difference in the percentage of CD56dim/CD16neg NK
cells between patients developing a sustained virological
response (SVR) and those who failed treatment, and hypothesize
that the higher proportion of CD56dim/CD16neg NK cells at base-
line and on treatment, which we describe to be associated with
SVR in patients with chronic HCV infection, could be due toJournal of Hepatology 2
nder CC BY-NC-ND license.increased proportions of dead cells in this particular NK subset.
Curiously, retrospective ﬂow cytometric analysis of their mono-
nuclear cell samples stored in liquid nitrogen revealed that the
vast majority of CD56dim/CD16neg NK cells (mean 95%) were actu-
ally composed of dead cells. In view of this unexpected ﬁnding,
Pembroke concludes that our data are not compatible with those
of others (which?), being ﬂawed by a purportedly high number of
dead cells in this speciﬁc NK-cell subset. Beside any technical con-
sideration, and even allowing for this being indeed the cause of
our ﬁndings, the ﬁrst comment that comes to one’s mind is why
would dead NK cells concentrate in SVR patients only and not in
non-responders (NR) or relapsers and why would they be013 vol. 59 j 908–913
conﬁned to the CD56dim/CD16neg subset? Unfortunately, we have
no plausible explanation for either question, nor do we have evi-
dence of such a high percentage of dead cells in our preparations
particularly in the CD56dim/CD16neg subset.
To check for possible ﬂaws in our analysis, we also went back
to our frozen samples, and examined the proportions of dead
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Fig. 1. Gating strategy. (A–F) Gating strategy to identify CD56dimCD16neg NK
cells in a representative SVR patient. (G) No differences between the proportions
of dead cells (mean ± SEM) in the CD56dim/CD16neg and CD56bright or CD16pos NK
subpopulations in SVR and NR patients.
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Journal of Hepatolocells in the various NK-cell subsets as indicated by Pembroke.
Moreover, we repeated the analysis of the prevalence of
CD56dim/CD16neg NK cells in an independent set of 10 patients,
5 SVR and 5 NR, to check whether there was any peculiarity in
our original cohort of patients [1]. Fig. 1A–F shows the gating
strategy to identify CD56dimCD16neg NK cells in a representative
SVR patient. Lymphocytes were gated by morphological features
(A) and NK cells identiﬁed as CD56pos/CD3neg (B) which were ana-
lyzed on the basis of CD56 and CD16 expression without exclud-
ing dead cells (C). Alternatively, dead cells were excluded by
gating ethidium monoazide (EMA) positive events which repre-
sented only 4.3% of the total number of events (D). Interestingly,
the proportion of CD56dim/CD16neg NK (F) obtained from NK cells
after exclusion of dead cells (E) was virtually identical to that
obtained without excluding EMApos cells (C), indicating that our
data were not inﬂuenced by an allegedly high concentration of
dead cells in the CD56dim/CD16neg NK subset, as suggested by
Pembroke et al. Moreover, Fig. 1G clearly shows that there
were no differences between the proportions of dead cells
(mean ± SEM) in the CD56dim/CD16neg and CD56bright or CD16pos
NK subpopulations in SVR and NR patients. Finally, we were
gratiﬁed to conﬁrm that, as already reported in our manuscript,
the percentages of CD56dim/CD16neg among SVR and NR were sig-
niﬁcantly different (mean ± SEM): 21.9% ± 4.3 vs. 6% ± 1.1, respec-
tively, p = 0.007, by including all cells, and 21.5% ± 4.2 vs.
5.8% ± 1.05, respectively, p = 0.007, after exclusion of dead cells,
also in this independent set of patients.
We believe that the above strongly corroborates our recently
published ﬁndings [1] and we are particularly grateful to,
Pembroke for allowing us to dispel any possible doubt regarding
the quality of our data.
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